Gilead Sciences Inc. said an analysis showed the company’s antiviral remdesivir reduced mortality rates in hospitalized patients with Covid-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.
Metabolic comorbidities, including obesity and type 2 diabetes increase the risk of morbidity and mortality in patients who contract coronavirus disease 2019 (Covid-19). But findings published in the journal Nature show that not only are patients with diabetes more at risk of more severe outcomes, patients without diabetes who develop Covid-19 may also be at a higher risk of actually developing diabetes following recovery.
Covid-19 was the primary or contributing cause of 377,883 deaths in the United States during 2021, with a particularly high toll among the elderly, according to a government report released on March 31.
Linda von Rosenvinge, IQ Practice Lead of Greater Than One, explores some of the reasons behind data mishaps and recommends remedies every healthcare marketer can incorporate into their research protocols.
California surpassed New York on Feb. 9 as the U.S. state with the most coronavirus deaths, a grim reminder of the pandemic’s toll even as the vaccine rollout and a sharp drop in new cases buoyed hopes of life eventually returning to normal.
A final analysis of the Phase III TITAN study shows that Janssen’s Erleada (apalutamide), when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.
Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.
A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
Chicago’s mayor issued a month-long stay-at-home advisory, and Detroit’s public schools called a halt to in-person instruction to curb the spread of the coronavirus as more than a dozen U.S. states reported a doubling of new Covid-19 cases in the last two weeks.
Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.